Writer and director Robert Rodriguez talks about inspiration behind his latest film, "We Can Be Heroes," and how he made it into a family affair.
Writer and director Robert Rodriguez talks about inspiration behind his latest film, "We Can Be Heroes," and how he made it into a family affair.
Eric Munchel and his mom allegedly talked of stashing weapons outside the Capitol, a pre-trial memo noted.
Lauren Carpenter reviews the Conference Championship games from Sunday as well news that Matthew Stafford is reportedly ready to leave Detroit. (Mike De Sisti / The Milwaukee Jo via Imagn Content Services, LLC)
Unless the United Kingdom is fundamentally reformed it could swiftly become a failed state as many people have lost faith in the way the country is governed by, and in the interests of, a London-centric elite, former Prime Minister Gordon Brown said. "I believe the choice is now between a reformed state and a failed state," Brown wrote in the Daily Telegraph newspaper. "It is indeed Scotland where dissatisfaction is so deep that it threatens the end of the United Kingdom."
A third fight against Poirier or one with Nate Diaz are among his options.
How can LV= increase our car insurance in the Covid-19 crisis?Although our car has rarely been used it has raised our premium by 15%
Britishvolt today announced the appointment of William Reynolds as Chief Financial Officer effective 1 January, 2021. Britishvolt's first UK battery Gigaplant with an investment of £2.6 billion will create over 3000 jobs. Mr. Reynolds has over 20 years of experience assisting companies with large-scale world-wide capital fund raising, strategic planning, financial and operations management and business development in Europe, the Americas, Asia and the Middle East.
DataGalaxy, an innovative start-up specializing in collaborative data cataloging and governance, has recently been recognized as one of the best places to work in France. During the assessment, The company received outstanding scores across several aspects of their workplace, such as learning opportunities, relationships and culture resulting in its recognition among the employer of choice in France.
Kosmos Energy (NYSE/LSE: KOS) announced today the following schedule for its fourth quarter 2020 results:
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2021) - NetCents Technology Inc. (CSE: NC) (FSE: 26N) (OTCQB: NTTCF) ("NetCents" or the "Company"), a cryptocurrency payments company, would like to provide a corporate update."We deeply appreciate your continued support as we work through this pandemic and paradigm-shift in how business is conducted. To say this year taught us a lot is an understatement. Our move to remote working was not as flawless as we would ...
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
Calgary, Alberta and Houston, Texas--(Newsfile Corp. - January 25, 2021) - PetroTal Corp. (TSXV: TAL) (AIM: PTAL) ("PetroTal" or the "Company") advises that, as announced by Gran Tierra Energy Inc. ("GTEI") on January 20, 2021, Gran Tierra Resources Limited ("GTRL") has sold an aggregate of 109,006,250 common shares in the Company ("Common Shares"). The Company understands that multiple entities purchased the shares sold by GTRL and that, following the sale, GTRL continues to ...
Kinnevik AB (publ) ("Kinnevik") will host a digital Capital Markets Day on 24 February 2021. The digital event will be held at 14.00-16.00pm CET on 24 February 2021 and includes an update on Kinnevik’s strategy, financial position and capital allocation framework. We will also present deep-dives into our focus sectors with participation from our investment organisation and the leadership of some of our companies. A link to the event and a detailed program will follow. Please register your participation no later than 19 February 2021 on our website: https://www.kinnevik.com/investors/cmd For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Investor Relations Phone +46 (0)70 762 00 50 Email firstname.lastname@example.org Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to make people’s lives better by providing more and better choice. In partnership with talented founders and management teams we build challenger businesses that use disruptive technology to address material, everyday consumer needs. As active owners, we believe in delivering both shareholder and social value by building long-term sustainable businesses that contribute positively to society. We invest in Europe, with a focus on the Nordics, the US, and selectively in other markets. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B. Attachment Press release
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19 Southampton, UK – 25 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces a clinical trial agreement to include its inhaled interferon beta-1a treatment (SNG001) in the ACTIV-2/A5401 Phase II/III trial in patients with COVID-19 not yet requiring hospitalisation. The trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). NIH’s Accelerating COVID-19 Therapeutic Inventions and Vaccines (ACTIV) (https://www.nih.gov/research-training/medical-research-initiatives/activ) is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-2 is a master protocol designed for evaluating multiple investigational agents compared to placebo in adults with mild-to-moderate COVID-19, not requiring hospitalisation. The Phase II/III ACTIV-2 study, led by the NIAID-funded AIDS Clinical Trials Group (ACTG), is an adaptive, randomised, blinded, placebo-controlled trial. The Phase II evaluation of SNG001 will see the recruitment of up to a maximum of 220 participants across US sites, in a home-based setting, split between SNG001 and placebo, and a positive result enables progression into the Phase III part of the study. NIAID is the regulatory sponsor and holder of the Investigational New Drug application to conduct the ACTIV-2 study, which is funded by Operation Warp Speed, a partnership led by the US Department of Health and Human Services through NIAID, to investigate and coordinate the development, manufacturing, and distribution of COVID-19 diagnostics, therapeutics and vaccines. Richard Marsden, CEO of Synairgen, said: “The inclusion of our inhaled interferon beta-1a treatment in the US Government-funded ACTIV-2 trial reflects the strong interest that our Phase II data has generated and the Company’s strong belief that this drug could play a vital role in the treatment of COVID-19. As an inhaled treatment, SNG001 offers ease of use that makes it possible for patients to administer it conveniently at home, reducing the risk of virus transmission during hospital visits and relieving the major logistical strain on healthcare systems. At-home treatments also have the potential to be taken much earlier in the course of the illness, preventing the progression of the virus in the lower respiratory tract and, in the scenario where hospitals are at capacity, treating patients in the home setting could be the only option. We hope to gain valuable data from this trial, which will aid us in progressing approval of SNG001 as a treatment for COVID-19.” In addition, Synairgen commenced dosing in an international 610 patient Phase III trial on 12 January 2021, assessing the efficacy of inhaled interferon beta in hospitalised patients with COVID-19. Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014. For further enquiries, please contact: Synairgen plcRichard Marsden, Chief Executive OfficerJohn Ward, Finance DirectorTel: + 44 (0) 23 8051 2800 finnCap (Nominated Advisor & Joint Broker)Geoff Nash, James Thompson, Charlie Beeson (Corporate Finance)Alice Lane, Sunila de Silva (ECM)Tel: + 44 (0) 20 7220 0500 Numis Securities Limited (Joint Broker)James Black, Freddie Barnfield, Duncan MonteithTel: +44 (0) 20 7260 1000 Consilium Strategic Communications (Financial Media and Investor Relations)Mary-Jane Elliott, Sue Stuart, Olivia Mansersynairgen@consilium-comms.comTel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen's differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people and those with co-morbidities such as heart and lung complications and diabetes are at greatest risk of developing severe or fatal disease. SNG001 (inhaled Interferon beta) applicability to COVID-19 Interferon beta ('IFN-beta') is a naturally occurring protein, which orchestrates the body's antiviral responses. It is used widely systemically for the treatment of multiple sclerosis and is a safe and well tolerated drug. There is growing evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in 'at-risk' patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses especially SARS-CoV-2, have evolved multiple mechanisms for suppressing endogenous IFN-beta production in the lung thereby helping the virus to evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells in vitro either prevents or greatly reduces viral replication to reduce the severity of infection and accelerate recovery. Recognising the importance of achieving high concentrations in the lung where SARS-CoV-2 exerts most of its tissue damaging effects, Synairgen's SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action. Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date. In July 2020, Synairgen announced the results of its Phase II double-blind, placebo-controlled study of 101 randomised COVID-19 hospitalised patients, which showed that SNG001 given for 14 days, was associated with greater odds of improvement versus placebo on the WHO Ordinal Scale for Clinical Improvement and more rapid recovery to the point where patients were no longer limited in their activity, with a greater proportion of patients recovering during the 28-day study period. The results were published in The Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial". Monk, P D et al., 12 November 2020, accessible here: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext. On 20 January 2021, Synairgen announced that it had completed recruitment of 120 COVID-19 patients (over the age of 65, or those over 50 with a comorbidity) in the home setting for its SG016 trial. Results from this study are expected in Q2 2021.
LOS ANGELES, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of AIT France (“AIT”), a manufacturer and distributor of innovative consumables for analytical chemistry and chromatography. With this acquisition, Calibre Scientific bolsters its strength in the chromatography market and continues to broaden its life sciences presence in Europe. Headquartered in Paris, France, AIT supplies public and private researchers and pharmaceutical laboratories. The company manufactures proprietary components and distributes a large range of consumables for chromatography and analytical chemistry, including exclusive distribution of products from numerous top brands. With the acquisition of AIT, Calibre Scientific gains a strategic partner to continue its growth in life sciences. “Integrating AIT into Calibre Scientific will further strengthen our activities and service capability in France and also enable us to plug AIT’s proprietary product portfolio into Calibre Scientific’s vast direct and distribution channels worldwide,” said Pascal Aznar, owner of AIT. Ben Travis, CEO of Calibre Scientific, had this to say about the acquisition: “AIT has developed deep and valuable partnerships across Europe due, in large part, to their expertise and customer service. These values mirror those of Calibre Scientific, and we look forward to building on those partnerships, combining AIT’s products with ours, and offering a more comprehensive solution for our customers.” About Calibre Scientific Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics, industrial, and biopharmaceutical communities. Calibre Scientific owns a portfolio of 16 life science and diagnostic companies, that have an unrivaled ability to address the unique challenges of their respective markets. Our global reach extends into over 100 countries, empowering customers all over the world. Headquartered in Los Angeles, California, Calibre Scientific continues to grow across a wide array of verticals and geographies, further expanding its product offering and global footprint to laboratories around the world. For more information, visit www.calibrescientific.com, or contact Brice Geoffrion, Director of Business Development, at email@example.com, or +1 (310) 651-8285.
The decision comes after New Zealand confirmed a case of the new South African strain of the virus.
Dutch police clashed with protestors demonstrating against coronavirus rules across the Netherlands on Sunday. Local media reported at least 240 people were detained nationwide. In central Amsterdam officers unleashed a water cannon after a row of mounted police and canine units moved in on a rally there with protesters throwing stones and fireworks, with banners that said "stop the lockdown." Thirty-six year old Melissa spoke to Reuters in downtown Amsterdam. "I do not agree with the actual politics in the Netherlands, the restrictions of freedom. The elderly are vulnerable, but there are also many young people who are vulnerable. And young people are the future of this country for me." Restaurant owners had organized the Amsterdam protest on the second day of tougher limits including a nightly curfew for the first time since World War II. Fearing a riot or a disease-spreading event, the Mayor designated the Museum square as a "high-risk zone" and gave police the power to pre-emptively frisk people for weapons. According to the national broadcaster, it was one of at least 10 cities where riot police had been deployed. It also said vehicles had been set on fire and there were reports of rioters looting stores. Schools and non-essential shops have been shut since mid-December, following the closure of bars and restaurants two months earlier. Overall, new infections in the country have been declining for a month, and fell again on Sunday.
Dr Fauci says Trump was never confrontational with him
Miley Cyrus will perform at the "TikTok Tailgate" for Super Bowl LV on Feb. 7, a concert for health care heroes. "I'll be there," Cyrus tweeted.
England are closing in on a series win.
Boohoo set for Debenhams deal, quarantines to impact on leisure stocks